Takayoshi Yamauchi
Overview
Explore the profile of Takayoshi Yamauchi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
931
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kajihara R, Long M, Hoki T, Chen H, Yamauchi T, Kanemaru H, et al.
J Immunother Cancer
. 2025 Jan;
13(1).
PMID: 39863301
Evidence has shown that T-cell receptors (TCRs) that recognize the same epitopes may not be the exact TCR clonotypes but have slightly different TCR sequences. However, the changes in the...
2.
Ishigaki H, Yamauchi T, Long M, Hoki T, Yamamoto Y, Oba T, et al.
Cancer Res Commun
. 2024 Jun;
4(7):1802-1814.
PMID: 38881188
Significance: Intratumoral T cells are composed of heterogeneous subpopulations with various phenotypic and transcriptional states. This study illustrates the intratumoral generation of antigen-specific CX3CR1+ CD8+ T cells that exhibit distinct...
3.
Abdelfatah E, Long M, Kajihara R, Oba T, Yamauchi T, Chen H, et al.
Cancer Res Commun
. 2023 Apr;
3(3):510-520.
PMID: 37009132
Significance: Current approaches to combined chemotherapy and anti-PD-1/PD-L1 therapy (chemo-immunotherapy) for patients with NSCLC are limited by the lack of reliable predictive biomarkers. This study shows the utility of T-cell...
4.
Shinchi H, Yuki M, Yamauchi T, Niimura M, Wakao M, Cottam H, et al.
ACS Appl Bio Mater
. 2022 Jan;
4(3):2732-2741.
PMID: 35014312
Toll-like receptors (TLRs) are pattern recognition receptors that activate innate immunity, and their ligands are promising adjuvants for vaccines and immunotherapies. Small molecule TLR7 ligands are ideal vaccine adjuvants as...
5.
Yamauchi T, Hoki T, Oba T, Kajihara R, Attwood K, Cao X, et al.
Cancer Immunol Immunother
. 2021 May;
71(1):137-151.
PMID: 34037810
The use of tumor mutation-derived neoantigen represents a promising approach for cancer vaccines. Preclinical and early phase human clinical studies have shown the successful induction of tumor neoepitope-directed responses; however,...
6.
Yamauchi T, Hoki T, Oba T, Jain V, Chen H, Attwood K, et al.
Nat Commun
. 2021 Mar;
12(1):1402.
PMID: 33658501
Immune checkpoint inhibitors (ICI) have revolutionized treatment for various cancers; however, durable response is limited to only a subset of patients. Discovery of blood-based biomarkers that reflect dynamic change of...
7.
Yamauchi T, Moroishi T
J Biochem
. 2020 Nov;
169(2):155-161.
PMID: 33226400
Extracellular vesicles (EVs) are small particles that are naturally released from various types of cells. EVs contain a wide variety of cellular components, such as proteins, nucleic acids, lipids and...
8.
Oba T, Hoki T, Yamauchi T, Keler T, Marsh H, Cao X, et al.
J Immunol
. 2020 Aug;
205(7):1867-1877.
PMID: 32848036
In vivo expansion of adoptively transferred CD8 T cells is a critical determinant of successful adoptive T cell therapy. Emerging evidence indicates Batf3-dependent conventional type 1 dendritic cells (cDC1s) rarely...
9.
Yamauchi T, Hoki T, Oba T, Saito H, Attwood K, Sabel M, et al.
JCI Insight
. 2020 Apr;
5(8).
PMID: 32255766
Although blockade of the programmed cell death 1/programmed cell death ligand 1 (PD-1/PD-L1) immune checkpoint has revolutionized cancer treatment, how it works on tumor-infiltrating CD8+ T cells recognizing the same...
10.
Patel S, Yamauchi T, Ito F
Surg Oncol Clin N Am
. 2019 May;
28(3):489-504.
PMID: 31079802
Adoptive T cell therapy for solid malignancies is limited because obtaining sufficient numbers of less-differentiated tumor-specific T cells is difficult. This roadblock can be theoretically overcome by the use of...